In a management-buyout, biocrea GmbH is taking over the CNS pipeline and phosphodiesterase enzyme (PDE) inhibitor platform from Finnish Biotie Therapies Corp.
The company currently has a pipeline of three PDE inhibitors at research and preclinical stages, which will be advanced into clinical development by 2012. The compounds have already demonstrated efficacy in preclinical animal models for schizophrenia, memory impairment, depression and anxiety.
biocrea is based in Radebeul near Dresden, Germany, and will be led by Dr. Tom Kronbach, former CSO of Biotie.
More details can be found soon at biocrea’s website.